The pharma company will work with MIT’s School of Engineering to establish an education program focused on developing new machine learning approaches to drug development and more.
The program, based at MIT’s Abdul Latif Jameel Clinic for Machine Learning in Health, or J-Clinic – which specializes in developing new healthcare AI tools – is funded with a three-year investment from Takeda and aims to leverage the expertise of both organizations.
With the collaboration, MIT will gain access to pharmaceutical infrastructure and expertise, and develop new educational program through J-Clinic that will support MIT faculty, students, researchers, and staff in their approach to AI development. The new program will combine algorithm and hardware innovations, and create multidimensional collaborations between academia and industry.
The MIT-Takeda Program will focus on funding as many as 10 flagship research projects per year in the areas of machine learning and health, including diagnosis of disease, prediction of treatment response, development of novel biomarkers, process control and improvement, drug discovery, and clinical trial optimization.
According to AI World Society (AIWS), AI technology for medical application can be a force for helping people achieve well-being and happiness, unleash their potential, obtain greater freedom, relieve them of resource constraints and solve important issues, such as SDGs.
The original article can be found here.